about
Left ventricular heart failure and pulmonary hypertensionScreening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration.Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care.Association between Embolic Stroke Patterns, ESUS Etiology, and New Diagnosis of Atrial Fibrillation: A Secondary Data Analysis of the Find-AF Trial.Association of glucose metabolism with diastolic function along the diabetic continuumMinimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial.Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease.Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.Elevated Plasma C-Terminal Endothelin-1 Precursor Fragment Concentrations Are Associated with Less Anxiety in Patients with Cardiovascular Risk Factors. Results from the Observational DIAST-CHF Study.Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life.Early pneumonia and timing of antibiotic therapy in patients after nontraumatic out-of-hospital cardiac arrest.A short form of the General Self-Efficacy Scale (GSE-6): Development, psychometric properties and validity in an intercultural non-clinical sample and a sample of patients at risk for heart failure.High-sensitivity troponin assay improves prediction of cardiovascular risk in patients with cerebral ischaemia.Cost-effectiveness of 7-day-Holter monitoring alone or in combination with transthoracic echocardiography in patients with cerebral ischemiaBlunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure.Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-DHF pilot study.Diagnosis of heart failure with preserved ejection fraction.Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.Heart failure awareness survey in Germany: general knowledge on heart failure remains poor.Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathy.Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function.Automatic detection of paroxysmal atrial fibrillation in patients with ischaemic stroke: better than routine diagnostic workup?Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study.An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems.Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction.Heart failure epidemiology 2000-2013: insights from the German Federal Health Monitoring System.Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure.Baroreflex activation therapy in patients with prior renal denervation.Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension.Prognostic impact of diastolic dysfunction in systolic heart failure-A cross-project analysis from the German Competence Network Heart Failure.Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial.Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design.Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial.Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin.Reverse epidemiology in different stages of heart failure.Long term biventricular support with Berlin Heart Excor in a Septuagenarian with giant-cell myocarditis.Cardiovascular Risk Factors in Central Retinal Artery Occlusion: Results of a Prospective and Standardized Medical Examination.Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.Cardiac function during mild hypothermia in pigs: increased inotropy at the expense of diastolic dysfunction.
P50
Q26778341-AFFB7F67-A8EF-4A68-A032-C60B745B4480Q30234524-7078CA7A-FBDD-4742-95D1-28FAA3CA44B9Q33321054-2C2A4C0A-D490-4944-9950-25CF0EEEA458Q33659829-2DFC3F56-5DFB-4757-BCB9-A7BBDCC4C882Q33880289-62490EE0-1E41-417E-B2F4-A6611DA0CAAEQ34281203-35B514D2-DF51-4D96-8DDF-DA965170DF5EQ34477958-60B2E09D-BA1F-42DD-95F3-EA2FC53D3F85Q34581918-15C40867-9581-4995-840B-B0A0EABAFE52Q35006600-2387DC49-7E36-4D61-A7DA-6FBEA4CDFA8FQ35760339-A7FEB415-E28E-49FA-AB5D-E9B67DE40D1DQ36084695-79EA19AA-9339-4520-8092-D9AEF1030726Q36531216-E3ECBBEE-75A3-41FD-9A71-019C6F513504Q36626204-462D5417-4068-4C19-BCCD-F83AE3C31ADDQ36756920-12514A6E-D2A4-4B24-967F-AB8F6E0344B8Q37303759-175B7D87-B551-41BE-858B-BD4101C87AC1Q37473209-2CFDC5B6-726B-453A-BFDC-C0B38CB5A7F2Q37625566-E07DEF9E-6086-44D3-8BBB-43EDF062B34AQ38224330-19A3023E-20A5-4087-AFCE-9427D94512AAQ38390657-CBC337E2-6A07-4F9A-A224-47CADF15F1B6Q38643984-3BCC3781-92AD-47D1-BB3B-682C9CBF4F91Q38644462-B94289F2-7DF3-45FA-B8A3-55EB30CED7A0Q38732534-2A6B9365-F2AA-4CF3-92DE-965582946D9CQ38786510-7D61732E-2F5B-4908-BB30-0ADD855904CCQ38826223-998D32D9-FA49-4CFD-9E16-E5D4411A545DQ39033294-E89D6A2A-FB3E-4701-8C91-B8C201C64A58Q39044220-8AC6E4D5-22E1-45FA-895B-14150800DC57Q39721193-BC4A4533-99F3-4637-B95C-06E7FE7D374AQ39729560-2AD3BEF5-A749-4A92-9EA0-A0F6D7A6A69BQ39802336-7FD6DFBB-8C77-4EBD-BD09-305CE06588D1Q39978343-CC5E1618-AF44-49EC-AD3E-3528E0E98C55Q40217312-6865D07A-79A7-404E-B48E-484F6CEB343EQ40340359-B5D16BFC-8952-4A45-8005-30950E40998FQ40459556-A63C707B-D1E1-4772-B991-310C1396223AQ41038079-521981FA-8D47-4380-83AF-2CC65017DD13Q41192744-B22975EA-A66A-498E-960D-373A0C363204Q41358655-546155F0-83D3-4481-9FE5-079E943E967BQ41512415-1FB3014B-6758-48B2-994B-130AF964957CQ41525632-D2544D81-E768-44F6-BC48-AA02DE2A001EQ41607888-2FD66B83-AA22-48B1-B641-79167069A21FQ43183941-0006CB3E-F196-4A51-8F56-4CD78BE1B2B9
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Rolf Wachter
@ast
Rolf Wachter
@en
Rolf Wachter
@es
Rolf Wachter
@nl
Rolf Wachter
@sl
type
label
Rolf Wachter
@ast
Rolf Wachter
@en
Rolf Wachter
@es
Rolf Wachter
@nl
Rolf Wachter
@sl
prefLabel
Rolf Wachter
@ast
Rolf Wachter
@en
Rolf Wachter
@es
Rolf Wachter
@nl
Rolf Wachter
@sl
P214
P106
P1153
12775831800
P21
P214
P31
P496
0000-0003-2231-2200
P735
P7859
viaf-62465063